A NON-VACCINE CURE for Coronavirus already exists!!

Reprinting verbatim with permission of THENHF.COM:

====

In a comparison of the antiviral potential of 6-azauridine, ribavirin, and glycyrrhizin against several pathogenic flaviviruses, Crance and collegues2
showed that ribavirin and 6-azauridine were active but not selective inhibitors when assessed with regard to inhibition of cell growth. Glycyrrhizin had a low selectivity index, but was a significantly potent inhibitor of replication of all the viruses tested. The EC50 reported by these authors for glycyrrhizin was 316–625 mg/L (added twice during the incubation period of 7 days). Taking into consideration that the compounds were added twice during the total period of incubation, the EC50 for glycyrrhizin we recorded (table) indicates a higher sensitivity of SARS-CV to this drug than that recorded by Crance and colleagues.
The mechanism of glycyrrhizin's activity against SARS-CV is unclear. Glycyrrhizin affects cellular signalling pathways such as protein kinase C; casein kinase II; and transcription factors such as activator protein 1 and nuclear factor κB. Furthermore, glycyrrhizin and its aglycone metabolite 18β glycyrrhetinic acid upregulate expression of inducible nitrous oxide synthase and production of nitrous oxide in macrophages.3
Nitrous oxide inhibits replication of several viruses—eg, Japanese encephalitis virus4
(a member of the Flaviviridae family), which can also be inhibited by glycyrrhizin.2
Our preliminary results show that glycyrrhizin induces nitrous oxide synthase in Vero cells and that virus replication is inhibited when the nitrous oxide donor (BETA NONOate) is added to the culture medium.
Glycyrrhizin has previously been used to treat patients with HIV-1 and chronic hepatitis C virus. The resulting low concentrations of P24 antigen in patients with HIV-1 who were given this compound has been attributed to upregulation of chemokines. Infrequent side-effects such as raised blood pressure and hypokalaemia were reported in some patients after several months of glycyrrhizin treatment. Treatment of SARS should only be needed for a short time. Since the side-effects of this compound are known and can be controlled for, proper monitoring could lead to effective use of glycyrrhizin as a treatment for SARS. Booth and colleagues5
reported that ribavirin had many toxic effects when given to patients with SARS, including haemolysis (76% of patients) and a drastic reduction of haemoglobin (49% of patients). However, although high doses of glycyrrhizin have been used in clinical trials, this compound had few toxic effects compared with the other regimens, and the drug was reported to be clinically effective.
Future search for compounds of therapeutic interest against SARS will be greatly facilitated by establishing growth of SARS-CV in human cells.

References

1. Drosten C Gunther S Preiser W et al.
Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
N Engl J Med. 2003; 348: 1967-1976

LINK: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13615-X/fulltext#fig1

==========

Why isn't the mainstream medical community (and their lapdog MSM) reporting this???

I think you know the answer....